NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing antiviral drugs, has announced additional details about its Phase II clinical trial of NV-387 Oral Gummies for the treatment of the current Bundibugyo Ebolavirus outbreak and other Ebola viruses in the Democratic Republic of Congo. The trial is proceeding as designed, with enrollment in Phase IIA beginning on or about September 23, 2026. This milestone is significant because it marks the first clinical evaluation of an oral antiviral candidate specifically for Ebola, a disease that has historically required complex and resource-intensive treatments.
Phase IIA is intended to identify an optimal, well-tolerated dosing regimen and serve as a go/no-go step before Phase IIB, a randomized controlled trial designed to evaluate efficacy. If successful, NV-387 could offer a major advantage in outbreak settings, where healthcare infrastructure is often limited. The oral gummy dissolves in the mouth without requiring water or swallowing effort, making it easy to administer in remote areas. This delivery method could dramatically simplify distribution and improve patient compliance compared to injectable therapies that require cold-chain storage and trained personnel.
NanoViricides characterized NV-387 as a broad-spectrum antiviral that mimics a host-side feature used by Ebola viruses, providing a rationale for potential activity against Bundibugyo and other Ebola strains. The drug is designed to attack the virus and reduce viral load. The company believes that an oral treatment could be readily deployed in resource-limited settings, which is critical given the recurring nature of Ebola outbreaks in Central and West Africa.
The trial’s progress comes amid ongoing efforts to develop more accessible antiviral therapies. NanoViricides’ lead drug candidate, NV-387, is also being developed for other viral infections, including RSV, COVID-19, Long COVID, Influenza, and MPOX/Smallpox. The company’s platform technology is based on TheraCour Pharma’s nanomedicine technology, which NanoViricides licenses for a range of human viral diseases.
For investors, the update is a reminder of the high-risk, high-reward nature of clinical-stage biotech. The company’s newsroom at https://ibn.fm/NNVC provides ongoing updates. More details on the trial can be found in the full press release at https://ibn.fm/zjg8X. The company’s website is www.nanoviricides.com.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers wire solutions via InvestorWire and other services. For more information, visit BioMedWire.
While the path to regulatory approval remains lengthy and uncertain, the initiation of Phase IIA for an oral Ebola treatment represents a potentially important step toward a more practical therapeutic option. If NV-387 proves safe and effective, it could become a valuable tool in future outbreak responses, particularly in regions where injectable drugs are difficult to deploy.
